New Two-Pronged attack tested for Tough-to-Treat ovarian cancer

This study is testing a new combination treatment for ovarian cancer that has returned after initial therapy. It combines a chemotherapy drug delivered directly into the abdomen with an immunotherapy drug given through the vein, aiming to better control the cancer. The trial involves about 24 participants and includes surgery to remove remaining tumor after several treatment cycles. The main goal is to see how well this approach shrinks tumors and how long patients live without the cancer getting worse.